CRISPR Therapeutics AG CRSP
54.23
(1.47)
(2.64%)
as of 25 Sep
- Market cap
- $5.4B
- P/E
- 0.0×
Follow CRSP
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(25.33%) | (30.18%) | (31.21%) | (26.09%) | |
| (21.70%) | (25.81%) | (23.24%) | (19.28%) | ||
ROIC |
(131,984.38%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(25.29%) | (29.79%) | (23.45%) | (19.22%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.32) | (3.85) | (4.18) | (3.85) | |
Free Cash Flow |
(303.14) | (345.93) | (401.18) | (371.32) | |
Capital Expenditures |
(0.65) | (0.91) | (1.21) | (1.74) | |
Piotroski F-Score |
1.00 | 1.00 | 2.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(7.89%) | (8.85%) | (8.26%) | (7.87%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.01 | 0.01 | 0.01 | 0.01 | |
Research and Development Expense of Revenue |
963.23% | 10,856.38% | 9,192.03% | 2,095.48% | |
Selling, General and Administrative Expense of Revenue |
191.11% | 2,095.21% | 1,740.90% | 523.19% | |
Share Based Compensation of Revenue |
199.21% | 2,065.50% | 1,672.22% | 510.16% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.62 | 0.59 | 0.70 | 0.82 | |
Depreciation/Fixed assets |
0.15 | 0.17 | 0.17 | 0.17 | |
Capex/Depreciation |
(0.03) | (0.05) | (0.06) | (0.09) | |
Revenue per Share |
0.42 | 0.04 | 0.04 | 0.14 | |
Operating CF per Share |
(3.31) | (3.84) | (4.16) | (3.83) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | |
Capex to Sales |
0.02 | 0.26 | 0.30 | 0.13 | |
Net Profit Margin |
(1,273.70%) | (16,569.77%) | (13,856.54%) | (3,368.72%) |
Columns are period end dates